Zheng Min
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer (NCT07348861) | Zheng Min | 2026-02-01 |
Track Zheng Min automatically
Every clearance here is in the API, with alerts when new ones post.